Effortless Measurement of All Four NADs and Glutathione for Laboratories

About

In response to the escalating demand from clinicians and researchers for precise and fast NAD measurement, NADMED unveils an innovative technology designed for extracting and measuring all four NADs and two glutathiones. The method is founded on colorimetric quantification, applicable to blood, tissue, or cells.

Distinguishing Feature of NADMED

The distinguishing feature of the NADMED method lies in its ability to measure metabolites individually, setting it apart from other methods and delivering exceptional accuracy comparable to mass spectrometry. Based on transparent scientific research from the University of Helsinki, NADMED’s technology presents fresh business opportunities for laboratories.

NADMED’s laboratory technology is available in kits, with the first EU IVDD compliant (CE-marked) kits for blood NAD+ and NADH already for sale. Kits for the remaining metabolites are slated for production by the year’s end.

Measuring NAD Metabolites and Glutathione

Measuring NAD metabolites and glutathione has long been hindered by the absence of a rapid and reliable method, impeding both research and the development of clinical applications for these REDOX molecules. NADMED’s technology presents a fast, scalable, and cost-effective solution. Unlike mass spectrometer analysis, which may take days, NADMED analysis yields results within hours. Moreover, NADMED makes this analysis accessible for laboratories without mass spectrometry, at a fraction of the total cost.

Jari Närhi, CEO of NADMED

“We believe that the NADMED method will advance science and medical practice by enabling larger and quicker clinical trials and in due course, diagnostics. NAD measuring should be seen as a first-line diagnostic tool in the future to fight for example degenerative diseases and metabolic disorders.”

For more information, please visit www.nadmed.com.

SourceNADMED

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”